Cargando…

The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response — Biological and Clinical Aspects

Radiation therapy remains an imperative treatment modality for numerous malignancies. Enduring significant technical achievements both on the levels of treatment planning and radiation delivery have led to improvements in local control of tumor growth and reduction in healthy tissue toxicity. Nevert...

Descripción completa

Detalles Bibliográficos
Autores principales:	Medová, Michaela, Aebersold, Daniel M., Zimmer, Yitzhak
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980615/ https://www.ncbi.nlm.nih.gov/pubmed/24378750 http://dx.doi.org/10.3390/cancers6010001

Ejemplares similares

The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer
por: Poliaková, Michaela, et al.
Publicado: (2018)

Deciphering MET‐dependent modulation of global cellular responses to DNA damage by quantitative phosphoproteomics
por: Bensimon, Ariel, et al.
Publicado: (2020)

A DNA-PK phosphorylation site on MET regulates its signaling interface with the DNA damage response
por: Koch, Jonas P., et al.
Publicado: (2023)

Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer
por: Piguet, Anne-Christine, et al.
Publicado: (2015)

Editorial: Exploiting DNA Damage Response in the Era of Precision Oncology
por: Zimmer, Yitzhak, et al.
Publicado: (2020)

PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models
por: Nisa, Lluís, et al.
Publicado: (2017)

A Comparative Analysis of Individual RAS Mutations in Cancer Biology
por: Muñoz-Maldonado, Carmen, et al.
Publicado: (2019)

CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks
por: Hovhannisyan, Lusine, et al.
Publicado: (2023)

Profiling Invasiveness in Head and Neck Cancer: Recent Contributions of Genomic and Transcriptomic Approaches
por: Nisa, Lluís, et al.
Publicado: (2015)

Prognostic and Predictive Biomarkers in Head and Neck Squamous Cell Carcinoma Treated with Radiotherapy—A Systematic Review
por: Schanne, Daniel H., et al.
Publicado: (2022)

c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma
por: Granito, Alessandro, et al.
Publicado: (2015)

Origin and evolution of plexins, semaphorins, and Met receptor tyrosine kinases
por: Junqueira Alves, Chrystian, et al.
Publicado: (2019)

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
por: Kentsis, Alex, et al.
Publicado: (2012)

AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis
por: Choi, Yun Jung, et al.
Publicado: (2019)

An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies
por: Orlando, Eleonora, et al.
Publicado: (2022)

Correction: An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies
por: Orlando, Eleonora, et al.
Publicado: (2023)

Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities
por: Zhang, Yazhuo, et al.
Publicado: (2018)

Proteolytic cleavages of MET: the divide-and-conquer strategy of a receptor tyrosine kinase
por: Fernandes, Marie, et al.
Publicado: (2019)

Expression and Prognostic Evaluation of the Receptor Tyrosine Kinase MET in Canine Malignant Melanoma
por: Koo, Karen, et al.
Publicado: (2023)

Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
por: Fujino, Toshio, et al.
Publicado: (2021)

Induction of MET Receptor Tyrosine Kinase Down-regulation through Antibody-mediated Receptor Clustering
por: Li, Wenjing, et al.
Publicado: (2019)

ProtRank: bypassing the imputation of missing values in differential expression analysis of proteomic data
por: Medo, Matúš, et al.
Publicado: (2019)

The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells
por: Welsh, James W, et al.
Publicado: (2009)

A new synaptic player leading to autism risk: Met receptor tyrosine kinase
por: Judson, Matthew C., et al.
Publicado: (2011)

MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma
por: Catenacci, Daniel V. T., et al.
Publicado: (2016)

Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase
por: Yao, Hang-Ping, et al.
Publicado: (2021)

The c-MET receptor tyrosine kinase contributes to neutrophil-driven pathology in cutaneous leishmaniasis
por: Passelli, Katiuska, et al.
Publicado: (2022)

The effect of inhibition of receptor tyrosine kinase AXL on DNA damage response in ovarian cancer
por: Yeo, Xun Hui, et al.
Publicado: (2023)

Synergistic effect of the TLR5 agonist CBLB502 and its downstream effector IL-22 against liver injury
por: Melin, Nicolas, et al.
Publicado: (2021)

MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy
por: Yao, Hang-Ping, et al.
Publicado: (2020)

Enhancing CRISPR deletion via pharmacological delay of DNA-PKcs
por: Bosch-Guiteras, Núria, et al.
Publicado: (2021)

Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
por: Qin, Anna, et al.
Publicado: (2023)

Targeting c‐met receptor tyrosine kinase by the DNA aptamer SL1 as a potential novel therapeutic option for myeloma
por: Zhang, Yibin, et al.
Publicado: (2018)

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
por: Yao, Yu, et al.
Publicado: (2023)

Cross talk of tyrosine kinases with the DNA damage signaling pathways
por: Mahajan, Kiran, et al.
Publicado: (2015)

The Met receptor tyrosine kinase prevents zebrafish primary motoneurons from expressing an incorrect neurotransmitter
por: Tallafuss, Alexandra, et al.
Publicado: (2008)

Hypoxia leads to decreased autophosphorylation of the MET receptor but promotes its resistance to tyrosine kinase inhibitors
por: Mekki, Meriem Sarah, et al.
Publicado: (2018)

MET Receptor Tyrosine Kinase Regulates Lifespan Ultrasonic Vocalization and Vagal Motor Neuron Development
por: Kamitakahara, Anna K., et al.
Publicado: (2021)

Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma
por: Demkova, Lucia, et al.
Publicado: (2018)

Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib
por: Agwa, Eberechi S, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rqrl0ggvshte2ea782t2u74cav